Leap Therapeutics, Inc.
LPTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $209 | $0 | $0 | $234 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $20,339 | $0 | $0 | $10,674 |
| Gross Profit | -$20,130 | $0 | $0 | -$10,440 |
| % Margin | -9,631.6% | – | – | -4,461.5% |
| R&D Expenses | $20,339 | $10,537 | $12,911 | $12,883 |
| G&A Expenses | $7,731 | $1,817 | $3,006 | $7,446 |
| SG&A Expenses | $7,731 | $1,817 | $3,006 | $8,246 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $800 |
| Other Operating Expenses | -$20,339 | $4,527 | $0 | $13,415 |
| Operating Expenses | $7,731 | $16,881 | $15,917 | $34,544 |
| Operating Income | -$27,861 | -$16,881 | -$15,917 | -$44,984 |
| % Margin | -13,330.6% | – | – | -19,223.9% |
| Other Income/Exp. Net | $1,892 | $238 | $482 | $2,777 |
| Pre-Tax Income | -$25,969 | -$16,643 | -$15,435 | -$42,207 |
| Tax Expense | $0 | $0 | $0 | -$2,097 |
| Net Income | -$25,969 | -$16,643 | -$15,435 | -$40,169 |
| % Margin | -12,425.4% | – | – | -17,166.2% |
| EPS | -0.08 | -0.4 | -0.37 | -0.37 |
| % Growth | 80% | -8.1% | 0% | – |
| EPS Diluted | -0.08 | -0.4 | -0.37 | -0.37 |
| Weighted Avg Shares Out | 41,445 | 41,445 | 41,269 | 41,252 |
| Weighted Avg Shares Out Dil | 41,445 | 41,445 | 41,269 | 41,252 |
| Supplemental Information | – | – | – | – |
| Interest Income | $123 | $246 | $437 | $595 |
| Interest Expense | $10 | $7 | $6 | $0 |
| Depreciation & Amortization | $775 | $0 | $0 | $702 |
| EBITDA | -$25,184 | -$16,636 | -$15,429 | -$20,193 |
| % Margin | -12,049.8% | – | – | -8,629.5% |